TRAIL receptor I (DR4) polymorphisms C626G and A683C are associated with an increased risk for hepatocellular carcinoma (HCC) in HCV-infected patients.
BMC cancer | 2012-03-08 | PMID 22401174
Körner Christian, Riesner Katarina, Krämer Benjamin and 9 more
